文献速递艾滋病与性传播感染

台湾第二代整合酶链转移抑制剂时代未接受抗逆转录病毒治疗的HIV-1感染者治疗前耐药趋势

Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

这项多中心研究纳入2016至2022年新诊断且未接受抗逆转录病毒治疗的HIV感染者3001例,检测治疗前耐药相关突变。结果显示NNRTI耐药率从2016年6.0%升至2022年13.1%(P=0.001),而NRTI、INSTI和PI耐药率保持稳定。

要点

  • NNRTI治疗前耐药率从2016年6.0%升至2022年13.1%(P=0.001)。
  • NRTI、INSTI和PI的治疗前耐药率分别稳定在2.1%、2.5%和0.4%。
  • 第二代INSTI引入后,INSTI治疗前耐药率仍保持低水平。

核心结论

  • 第二代INSTI引入台湾后,HIV-1对NRTI和INSTI的治疗前耐药趋势保持低水平。
  • 2016至2022年间NNRTI治疗前耐药率未见显著下降。

研究设计与样本

  • 多中心研究,纳入2016至2022年新诊断且未接受抗逆转录病毒治疗的HIV感染者3001例,占同期台湾新诊断HIV感染者的24.3%。
  • 进行治疗前基因型耐药检测、HIV-1亚型分析,并测定血浆HIV RNA载量和CD4淋巴细胞计数。
  • 使用斯坦福大学HIV耐药数据库分析耐药相关突变,仅纳入导致至少低水平耐药的突变。

主要发现

  • 可分析基因序列的感染者中,NNRTI、NRTI、第一代和第二代INSTI及PI的治疗前耐药率分别为10.0%、2.1%、2.5%、0.6%和0.4%。
  • NRTI、INSTI和PI的治疗前耐药趋势保持稳定。
  • NNRTI治疗前耐药率从2016年6.0%显著上升至2022年13.1%(P=0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Monitoring the trends of pre-treatment drug resistance (PDR) and resistance-associated mutations (RAMs) among antiretroviral-naïve people with HIV (PWH) is important for the implementation of HIV treatment and control programmes. We analysed the trends of HIV-1 PDR after the introduction of second-generation integrase strand-transfer inhibitors (INSTIs) in 2016 in Taiwan, when single-tablet regimens of non-nucleoside reverse-transcriptase inhibitor (NNRTI-) and INSTI-based antiretroviral therapy became the preferred treatments. MATERIALS AND METHODS: In this multicentre study, we included newly diagnosed, antiretroviral-naïve PWH who underwent tests for RAMs between 2016 and 2022. Pre-treatment genotypic resistance testing was performed, along with HIV-1 subtyping and determinations of plasma HIV RNA load and CD4 lymphocyte counts. RAMs were analysed using the Stanford University HIV Drug Resistance Database and only RAMs conferring at least low-level resistance were included. RESULTS: From 2016 to 2022, pre-treatment blood samples from 3001 newly diagnosed PWH, which constituted 24.3% of newly diagnosed PWH in Taiwan during the study period, were tested. Of the PWH with analysable gene sequences, the HIV-1 PDR prevalence to NNRTIs, nucleoside reverse-transcriptase inhibitors (NRTIs), first- and second-generation INSTIs and PIs was 10.0%, 2.1%, 2.5%, 0.6% and 0.4%, respectively. While the trends of PDR remained stable for NRTIs, INSTIs and PIs, there was a significantly increasing trend of PDR to NNRTIs from 6.0% in 2016% to 13.1% in 2022 (P = 0.001). CONCLUSIONS: After the introduction of second-generation INSTIs in Taiwan, the trends of HIV-1 PDR to NRTIs and INSTIs remained low. Furthermore, there was no significant decrease of the prevalence of PDR toward NNRTIs between 2016 and 2022.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chen GJ, Cheng CY, Yang CJ, et al. Trends of pre-treatment drug resistance in antiretroviral-naïve people with HIV-1 in the era of second-generation integrase strand-transfer inhibitors in Taiwan. J Antimicrob Chemother. 2024. PMID: 38546761. doi:10.1093/jac/dkae086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。